TRCT
DMAC icon

Tower Research Capital (TRC)’s DiaMedica Therapeutics DMAC Stock Holding History

Tower Research Capital (TRC)’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.5K Buy
5,090
+3,706
+268% +$29.4K ﹤0.01% 3065
2025
Q4 		$11K Sell
1,384
-1,338
-49% -$10K ﹤0.01% 3662
2025
Q3 		$18.7K Buy
+2,722
New +$14.8K ﹤0.01% 3370
2025
Q2 		– Sell
-738
Closed -$2.8K – 5320
2025
Q1 		$2.8K Buy
+738
New +$4.22K ﹤0.01% 4506
2024
Q4 		– Sell
-1,118
Closed -$4.68K – 5749
2024
Q3 		$4.68K Sell
1,118
-770
-41% -$2.84K ﹤0.01% 4451
2024
Q2 		$5.57K Sell
1,888
-808
-30% -$2.22K ﹤0.01% 4671
2024
Q1 		$7.47K Sell
2,696
-4,568
-63% -$13.3K ﹤0.01% 4197
2023
Q4 		$20.6K Buy
7,264
+3,503
+93% +$8.67K ﹤0.01% 3627
2023
Q3 		$9.7K Sell
3,761
-2,479
-40% -$7.96K ﹤0.01% 4189
2023
Q2 		$27K Buy
6,240
+254
+4% +$617 ﹤0.01% 3123
2023
Q1 		$9K Buy
5,986
+2,302
+62% +$3.65K ﹤0.01% 4477
2022
Q4 		$6K Buy
3,684
+2,706
+277% +$3.64K ﹤0.01% 4704
2022
Q3 		$1K Sell
978
-1,792
-65% -$2.8K ﹤0.01% 5752
2022
Q2 		$6K Buy
2,770
+1,102
+66% +$2.57K ﹤0.01% 4910
2022
Q1 		$5K Sell
1,668
-7,692
-82% -$21.8K ﹤0.01% 5038
2021
Q4 		$35K Buy
9,360
+7,890
+537% +$31K ﹤0.01% 3078
2021
Q3 		$6K Sell
1,470
-3,479
-70% -$13.3K ﹤0.01% 4740
2021
Q2 		$22K Buy
4,949
+4,039
+444% +$33.1K ﹤0.01% 3794
2021
Q1 		$8K Buy
+910
New +$8.5K ﹤0.01% 4461
2020
Q4 		– Sell
-1,383
Closed -$6K – 5166
2020
Q3 		$6K Buy
+1,383
New +$7.32K ﹤0.01% 4283
2019
Q2 		– Sell
-71
Closed – – 3808
2019
Q1 		$0 Buy
+71
New +$256 ﹤0.01% 3876

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s DMAC Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its DiaMedica Therapeutics (DMAC) stake by 268% in Q1 2026, buying an estimated $29.4K and bringing the position to 5,090 shares worth $34.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Tower Research Capital (TRC) first reported a position in DMAC in Q1 2019 and has held it in 21 quarters since. The position peaked at $35K in Q4 2021. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Tower Research Capital (TRC) held 5,090 shares of DiaMedica Therapeutics worth $34.5K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,706 DiaMedica Therapeutics shares in Q1 2026, an estimated $29.4K.
  • DiaMedica Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3065 holding.
  • Tower Research Capital (TRC) first reported a position in DiaMedica Therapeutics in Q1 2019 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s DiaMedica Therapeutics position peaked at $35K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.